NCT06342414 An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
| NCT ID | NCT06342414 |
| Status | Recruiting |
| Phase | — |
| Sponsor | City of Hope Medical Center |
| Condition | Hepatocellular Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2024-03-15 |
| Primary Completion | 2028-06-18 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2024-03-15 with a primary completion date of 2028-06-18.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
It is sometimes difficult to precisely understand whether a primary liver cancer is a hepatocellular carcinoma or a cholangiocarcinoma. The researchers will develop and validate a liquid biopsy, based on exosomal content analysis and powered by machine learning, to help clinicians differentiate these two cancers before surgery.
Eligibility Criteria
Inclusion Criteria: * A histologically confirmed diagnosis of hepatocellular carcinoma * A histologically confirmed diagnosis of intrahepatic cholangiocarcinoma * Received standard diagnostic and staging procedures as per local guidelines * Availability of at least one blood-derived sample, drawn before receiving any curative-intent treatment Exclusion Criteria: * Lack of or inability to provide informed consent * Synchronous hepatocellular carcinoma and intrahepatic cholangiocarcinoma * Primary liver cancer other than hepatocellular carcinoma or intrahepatic cholangiocarcinoma * Secondary liver cancer
Contact & Investigator
Ajay Goel, PhD
PRINCIPAL INVESTIGATOR
City of Hope Medical Center
Frequently Asked Questions
Who can join the NCT06342414 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06342414 currently recruiting?
Yes, NCT06342414 is actively recruiting participants. Contact the research team at AJGOEL@COH.ORG for enrollment information.
Where is the NCT06342414 trial being conducted?
This trial is being conducted at Duarte, United States, Fukuoka, Japan, Kumamoto, Japan, Sapporo, Japan and 1 additional location.
Who is sponsoring the NCT06342414 clinical trial?
NCT06342414 is sponsored by City of Hope Medical Center. The principal investigator is Ajay Goel, PhD at City of Hope Medical Center. The trial plans to enroll 400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.